Today: 17 May 2026
Commonwealth Bank shares buck ASX slide as RBA rate-hike talk returns — here’s what traders watch next
3 March 2026
1 min read

Commonwealth Bank shares buck ASX slide as RBA rate-hike talk returns — here’s what traders watch next

Sydney, March 3, 2026, 17:00 AEDT — The session has ended.

Shares of Commonwealth Bank of Australia edged up Tuesday, outpacing a wider decline as investors digested changing interest-rate expectations and surging energy prices.

CBA finished the session 0.28% higher at A$173.98, having moved within a range of A$172.56 to A$174.76.

That resilience stood out, with the S&P/ASX 200 dropping 1.34% to 9,077.30 and investors scrambling for safer ground in a jittery session.

Markets worldwide have flipped to risk-off as the Middle East conflict expands, and rising oil and gas prices are stoking fresh inflation fears—right when central banks were working hard to anchor expectations.

Reserve Bank of Australia Governor Michele Bullock, speaking in Sydney, pointed to fresh data backing the RBA’s February rate hike. Bullock flagged ongoing geopolitical turbulence as a factor clouding the inflation outlook. The cash rate sits at 3.85%, she said, and the central bank is “well positioned” to act if circumstances shift. Reuters

Attention now turns to Wednesday’s GDP figures, out March 4, with traders recalibrating odds for the March 17 policy decision. According to Reuters, market pricing still hovers near a 30% probability for a 25-basis-point hike. Both CBA and National Australia Bank have upped their fourth-quarter growth forecasts to around 1%. CBA’s Ashwin Clarke pointed out the economy is running “well above” potential, which he says heightens the chance of a move this March. Reuters

Bank stocks face a double-edged sword with rates. Yes, higher rates help boost lending margins. On the flip side, they send funding costs up and could pressure borrowers—particularly if the oil shock sticks and strains family budgets.

Commonwealth Bank didn’t put out any new statements on Tuesday that traders noticed. Instead, focus has shifted to the upcoming interim dividend—A$2.35 a share, set for payout on March 30, as listed on CBA’s dividend information page.

The macro picture can easily swing the other way. Say GDP comes in softer, or oil prices tumble—suddenly, the rate-hike buzz fades fast. Stretch that energy shock out, though, and the mood shifts: credit quality worries could resurface before year-end.

CBA holders are eyeing Wednesday’s GDP figure, with the RBA’s March 17 meeting following close behind. Both are set to jolt bond yields, and bank share prices are expected to react swiftly after.

Stock Market Today

  • Realty Income (O) Faces Mixed Valuation Signals After Solid Q1 and Raised AFFO Guidance
    May 17, 2026, 12:49 AM EDT. Realty Income (O) reported strong Q1 results and boosted its Adjusted Funds From Operations (AFFO) guidance, alongside its 671st monthly dividend, equity issuance, and buybacks. Despite these positive developments, its share price fell 6.1% over 30 days and 6.9% over 90 days. The stock trades at a high price-to-earnings (P/E) ratio of 50.9x, well above peer averages, suggesting valuation risk. However, a dividend-focused valuation model indicates the stock is 13.8% undervalued with a fair value of $70.93 compared to the current $61.12 share price. Investors should weigh steady dividend growth and operating margins against rising funding costs and regional revenue risks in Realty Income's western markets.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 03.03.2026

Westpac share price holds at A$41.80 as RBA flags March hike risk and GDP looms
Next Story

Westpac share price holds at A$41.80 as RBA flags March hike risk and GDP looms

Go toTop